ArticleJournal of acute medicine2026
Epigallocatechin-3-gallate Modulates Hyperglycemia-Triggered Macrophage Autophagy Through miR-204-5p Suppression: Implication for Acute Cardiometabloic Injury.
Article in Journal of acute medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epigallocatechin-3-gallate (EGCG) possess many biological properties. Autophagy and inflammation interact to cause cardiovascular diseases, and diabetic cardiovascular diseases; hyperglycemia- and hyperinsulinemia-induced microRNA reduction in the diabetic heart contribute to poor survival and increased infarct size in diabetic myocardial ischemia/reperfusion. However, whether EGCG affects macrophage autophagy and microRNA 204-5p (miR-204-5p) regulation under hyperglycemic conditions remain unclear. In this report, we investigated the effects of EGCG on the molecular regulatory mechanisms of miR-204-5p in LC3B macrophage autophagy under hyperglycemic stimulation conditions. Reverse transcription and real-time quantitative polymerase chain reaction, western blots, and luciferase activity assay were performed. Macrophages were cultured with 5.5 mM (low glucose) and 25 mM (high glucose) for hyperglycemia stimulation, and hyperglycemia was induced for 1 hour. EGCG attenuated cytoplasmic miR-204-5p levels under hyperglycemia stress in time-course and concentration dependent manners. Hyperglycemic treat-EGCG augmented the macrophage autophagy marker LCB mRNA by under hyperglycemia stress in a time-dependent manner significantly. Treatment with EGCG (10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.